Stipple Bio has $100 million, an ADC program poised for clinical studies, and a problem only the company can solve: nobody outside the building knows what it's actually targeting.
The Cambridge, Massachusetts biotech emerged from stealth last week with one of the larger Series A rounds in recent oncology memory, co-led by RA Capital, a16z Bio+Health, and Nextech Invest. Its lead asset, STP-100, is an antibody-drug conjugate, or ADC, designed to bind tumor-specific epitopes rather than the conventional targets most ADC developers have already crowded into. Stipple plans to put it into clinical studies in early 2027, according to a company press release.
What it did not say: the target. Or the indication. Or how the company's Pointillist epitope-discovery platform identified the binding site it is now betting on.
That kind of deliberate silence is unusual in oncology drug development, where investor confidence typically depends on a named target with a known mechanism. Companies keep targets private when the science is still fragile or when the competitive situation makes disclosure look worse than quiet. Stipple has done neither a publication nor a conference presentation that would explain its choice. Multiple ADC developers at AACR 2026 listed their targets in abstracts. Stipple did not file.
"Companies keep their target private when the science is still fragile or when the competitive situation makes it look worse to disclose," said one oncology investor at a different firm who asked not to be named because they had not reviewed Stipple's specifics. "That's not unusual. What's unusual is that they raised this much without naming it."
The founding team is the credibility play. Aaron Ring, an associate professor and Anderson Family Chair for Immunotherapy at the Fred Hutchinson Cancer Center, has built a reputation for work on how tumor cells display abnormal surface markers. Aashish Manglik, an associate professor of pharmaceutical chemistry at the University of California, San Francisco, brings structural biology and protein engineering depth. They founded the company in 2022 and seeded it with backing from a16z Bio+Health and Emerson Collective Investments before hiring Jeff Landau as CEO in April 2025. Landau spent the previous decade at CytomX Therapeutics, a biotech that built its identity around tumor-selective therapeutics.
The Pointillist platform, according to Stipple's website, identifies tumor-specific cell surface epitopes across multiple modalities, meaning the same discovery engine could theoretically feed an ADC, a bispecific antibody, or a radiopharmaceutical. That breadth is the platform pitch. Whether it has produced a genuinely differentiated target for STP-100, or whether it found an epitope on a known target that others have already characterized, is not something the company has disclosed.
The ADC field has moved fast. There are now more than 15 FDA-approved ADCs, and the pipeline is substantially larger than the approved set. The most common targets, HER2, TROP2, and EGFR, are so crowded that developers increasingly frame themselves as next-generation by emphasizing tumor-selectivity rather than target novelty. Stipple is attempting to do both: find a novel target with a novel platform. That is a harder bet than finding a novel target on an established platform, and the company has not given investors enough information to evaluate which version of that story they are actually running.
There is a smaller detail that is easy to miss. The company's About page, as of last week, listed Michelle Zhang as Chief Executive Officer in one biography block while the leadership roster named Jeff Landau as CEO and Zhang as chief scientific officer. The inconsistency does not change who runs the company, but it is the kind of thing that happens when a company moves fast in stealth, and it is the kind of thing investors doing deep diligence typically find before the press release goes out.
Stipple Bio says the Series A should fund it into 2029, according to its press release. That timeline puts a Phase 1 readout somewhere in 2028 at the earliest, assuming no clinical pauses. By then, the ADC field will look different. More programs will have entered the clinic. More targets will have been validated or abandoned. The undisclosed target will no longer be undisclosed.
The question is whether the answer, when it comes, will be worth the wait.
Stipple Bio declined to comment on the target, indication, or platform specifics.
